followed. 1 Many of the scientists concerned argued on the basis that science should operate in isolation from the norms which govern society as a whole, a point emphasised in an excellent letter to The Times, 2 by Philip McCarthy, which is worth quoting again: We live in an era unique in history for its uncritical and reverent attitude to scientific opinion, usually referred to as 'expert ' . Scientists have been placed on the pedestals vacated by politicians and priests. This in spite of the fact that most scientific forecasts fail to materialise. Scientists are not the guaranteed channels to truth, and their moral opinions are as valid and invalid as the rest of ours. I speak as an admirer of good science, but a greater admirer of critical thinking.
Sadly, the quality of the debates in the House of Commons, leading to its Third Reading on 22 October 2008, and of the accompanying coverage in the media, was no better, as appeals to both politicians and scientists to take a less-biased and morecritical approach had fallen on deaf ears. 3 This was partly because the embryologists in the Scientific Establishment, seeing funding and fame for themselves and their colleagues if animal-human cybrid embryos were seen as the only way of producing pluripotent human stem cells, had been dismissive of the prospects for producing these cells of great potential for research and testing from postembryonic tissues, including umbilical cord blood and adult bone-marrow and skin. As a result, and because of the way research funding is controlled in the UK, it had become clear that the UK is not investing enough in research on adult stem cells, as a result of which we will fall behind in the development of new therapies for many serious diseases, and some of our best scientists will emigrate to work in countries where their work is viewed more favourably. 3 It could be argued that this particularly applied to work aimed at developing human cell-based toxicity test procedures to replace the conventional animal tests, the value of which will always be compromised by species differences. But this issue was given little or no attention in the Parliamentary debates, presumably because it was of little interest to the scientists who lobbied the politicians.
On the international front, it was very encouraging to see an article by Robert Chapin and Donald Stedman, published in Toxicological Sciences in 2009, entitled Endless Possibilities: Stem Cells and the Vision for Toxicity Testing in the 21st Century. 4 The authors successfully combined caution with enthusiasm, and emphasised the need to avoid confusing perspicacity (seeing what is envisaged) with propinquity (getting close to achieving it). They drew attention to the great importance of the production of induced pluripotent stem (iPS) cells from differentiated cells, proclaimed by Science to be the Breakthrough of the Year in 2008. 5 The great appeal of iPS cells is that they are derived from adult cells, so the production and killing of embryos (including cybrids) is not necessary, they could start from the ultimate recipient of any therapy based on them, thus avoiding immune rejection, and they could be used to produce valuable cell lines from individuals with specific diseases or genetic traits.
One link between stem cells and the toxicity testing vision would be to focus on specific pathways and networks of genes, with patterns of response linked to in vivo toxicity profiles. Here, hepatocytes, cardiomyocytes and neurons would be of particular interest, because of their involvement in major manifestations of toxicity.
Nevertheless, all is not lost in the UK, where we now have the Stem Cells for Safer Medicines consortium, formed at about the time when the Human Fertilisation and Embryology Bill 2007-08 was making its way through the House of Commons, to enable the creation of a bank of stem cells, open protocols and standardised systems in stem cell technology that will enable consistent differentiation of stem cells into stable homogenous populations of particular cell types, with physiologically relevant phenotypes suitable for toxicology testing in high-throughput platforms. 6 October 2008 also saw the announcement of an international collaboration on stem cell research involving the Medical Research Council (MRC) and the California Institute for Regenera tive Medicine (CIRM), 7 which is primarily focused on the devel-Editorial Adult Human Stem Cells and Toxicity Testing: Realising the Potential opment of novel therapies for the treatment of acute and chronic disease and serious injury. In May 2009, Lord Drayson reported to the House of Lords that the MRC had set aside £5 million for the UK component of the collaborative proposals, and that the total CIRM budget was for $200 million, which involved a number of other partners in addition to the MRC. 8 My interest is this topic was revived by an article in The Times on 4 May 2010, entitled New stem cells will reduce the need for animal testing, 9 which stood out in contrast to the saturation coverage of the General Election which was to take place later that week. Mark Henderson, the paper's Science Editor, had been talking to James Thomson of the University of Wisconsin, one of the founders of Cellular Dynamics International, who was named in 2007 as one of TIME Magazine's 100 Most Influential People in the World. The company produces iCell™ Cardiomyocytes from human iPS cell-derived cardiomyocytes, and has developed an assay for identifying molecules involved in hERG channel blocking. 10 The use of the assay has led to the removal from the market of a number of drugs implicated in the induction of long QT syndrome (LQTS) in certain individuals and in increasing the potential for death from arrhythmia.
Cellular Dynamics International now intends to produce heart cells by using iPS cells from individuals from particular genetic backgrounds or with specific genetic traits, to see, for example, whether candidate drugs could have selective side-effects in such individuals. 9 The advantages of such an approach over the use of traditional animal procedures are obvious.
During the passage of the Human Fertilisation and Embryology Bill 2007-08, The Times did not show much enthusiasm for the development of procedures based on pluripotent stem cells from postembryonic tissues, but I hope that Mr Henderson will now become more sympathetic to the view that the production of animal-human cybrids is not necessary, desirable though it may be to some with vested interests in the promotion of cybrid embryo technology. 
Michael Balls

